Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells

PLoS One. 2016 Jun 3;11(6):e0156063. doi: 10.1371/journal.pone.0156063. eCollection 2016.

Abstract

Crosslinking of regulatory immunoreceptors (RR), such as BDCA-2 (CD303) or ILT7 (CD85g), of plasmacytoid dendritic cells (pDCs) efficiently suppresses production of type-I interferon (IFN)-α/β and other cytokines in response to Toll-like receptor (TLR) 7/9 ligands. This cytokine-inhibitory pathway is mediated by spleen tyrosine kinase (Syk) associated with the ITAM-containing adapter of RR. Here we demonstrate by pharmacological targeting of Syk that in addition to the negative regulation of TLR7/9 signaling via RR, Syk also positively regulates the TLR7/9 pathway in human pDCs. Novel highly specific Syk inhibitor AB8779 suppressed IFN-α, TNF-α and IL-6 production induced by TLR7/9 agonists in primary pDCs and in the pDC cell line GEN2.2. Triggering of TLR9 or RR signaling induced a differential kinetics of phosphorylation at Y352 and Y525/526 of Syk and a differential sensitivity to AB8779. Consistent with the different roles of Syk in TLR7/9 and RR signaling, a concentration of AB8779 insufficient to block TLR7/9 signaling still released the block of IFN-α production triggered via the RR pathway, including that induced by hepatitis B and C viruses. Thus, pharmacological targeting of Syk partially restored the main pDC function-IFN-α production. Opposing roles of Syk in TLR7/9 and RR pathways may regulate the innate immune response to weaken inflammation reaction.

MeSH terms

  • Cytokines / metabolism
  • Dendritic Cells / drug effects
  • Dendritic Cells / metabolism*
  • Humans
  • Immunity, Innate
  • Phosphorylation / drug effects
  • Protein Kinase Inhibitors / pharmacology
  • Signal Transduction / drug effects
  • Signal Transduction / physiology*
  • Syk Kinase / antagonists & inhibitors
  • Syk Kinase / metabolism*
  • Toll-Like Receptors / agonists
  • Toll-Like Receptors / metabolism*

Substances

  • Cytokines
  • Protein Kinase Inhibitors
  • Toll-Like Receptors
  • Syk Kinase

Grants and funding

Grantova agentura Ceske republiky (Czech Science Foundation) 14-32547S (http://gacr.cz/) DK AFH KT JH IH. Fondation ARC pour la Recherche sur le Cancer, PJA 20131200304, (http://www.fondation-arc.org/) BA JAN DO IH RS. Fondation pour la Recherche Medicale, SPF20121226309, (http://www.frm.org/) RS. BIOCEV – Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University“ (CZ.1.05/1.1.00/02.0109), from the European Regional Development Fund (http://www.biocev.eu/) IH. Ligue contre le cancer (http://www.ligue-cancer.net/) BA. Algerian Ministry of Higher Education and Research, and Franco-Algerian Cooperation BA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. SL is an employee of AB Science. AB Science provided support in the form of salary for author SL, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the ‘author contributions’ section.